Projekt
MSD-MK-3475 KEYNOTE 937
Laufend - Rekrutierung – laufend · 2019 bis 2026
Semela David, Stillhard Roman
Art
Klinische Forschung
Reichweite
Multizentrisch, KSSG als teilnehmendes Zentrum
Bereiche
Status
Laufend - Rekrutierung – laufend
Start
2019
Ende
2026
Finanzierungsart
Industrie
Studiendesign
Study Phase: Phase 3
Adjuvant treatment of HCC
Population Participants with complete radiological response after surgical resection of Stage IB, II and III HCC per American Joint Committee on Cancer (AJCC) 8th Edition with adaptations based on tumor characteristics as established by the pathology report or complete radiological response after local ablation
Schlagwörter (Tags)
HCC
Adjuvant Therapy
Label
Leberkrebs
Kurzbeschreibung/Zielsetzung
A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and
Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant herapy in Participants ith Hepatocellular Carcinoma and Complete Radiological Response after Surgical esection or Local Ablation (KEYNOTE-937)